Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Increased by Intech Investment Management LLC

Intech Investment Management LLC boosted its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 70.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 31,571 shares of the biotechnology company’s stock after buying an additional 13,060 shares during the period. Intech Investment Management LLC’s holdings in Blueprint Medicines were worth $2,754,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Quarry LP acquired a new position in Blueprint Medicines in the third quarter valued at approximately $32,000. R Squared Ltd acquired a new position in Blueprint Medicines in the fourth quarter valued at approximately $51,000. Asset Management One Co. Ltd. acquired a new position in Blueprint Medicines in the fourth quarter valued at approximately $88,000. Van ECK Associates Corp boosted its stake in Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 363 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Blueprint Medicines in the third quarter valued at approximately $108,000.

Insiders Place Their Bets

In other news, insider Ariel Hurley sold 2,250 shares of Blueprint Medicines stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now owns 14,967 shares in the company, valued at approximately $1,496,700. The trade was a 13.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,334 shares of company stock worth $3,103,512 over the last quarter. Company insiders own 4.21% of the company’s stock.

Blueprint Medicines Stock Up 1.0 %

NASDAQ BPMC opened at $90.48 on Thursday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The firm has a 50-day simple moving average of $99.49 and a 200 day simple moving average of $93.96. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90. The stock has a market cap of $5.78 billion, a PE ratio of -83.78 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BPMC shares. JMP Securities reiterated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. HC Wainwright reiterated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Jefferies Financial Group started coverage on Blueprint Medicines in a research report on Monday. They set a “buy” rating and a $135.00 price objective for the company. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Finally, Scotiabank started coverage on Blueprint Medicines in a research report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price objective for the company. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $125.70.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.